In this setting, the risk of developing vitiligo and AA in patients with AS, CD, or UC treated with anti-TNF therapy compared to those without anti-TNF agents has been evaluated using the Korea National Health Insurance Claims databases [32]. This evidence concerns the gene TNF and vitiligo.